Myeloid growth factors.
Crawford
Jeffrey
J
Duke Comprehensive Cancer Center.
Armitage
James
J
Balducci
Lodovico
L
Bennett
Charles
C
Blayney
Douglas W
DW
Cataland
Spero R
SR
Dale
David C
DC
Demetri
George D
GD
Erba
Harry P
HP
Foran
James
J
Freifeld
Alison G
AG
Goemann
Marti
M
Heaney
Mark L
ML
Htoy
Sally
S
Hudock
Susan
S
Kloth
Dwight D
DD
Kuter
David J
DJ
Lyman
Gary H
GH
Michaud
Laura Boehnke
LB
Miyata
Sarah C
SC
Tallman
Martin S
MS
Vadhan-Raj
Saroj
S
Westervelt
Peter
P
Wong
Michael K
MK
D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects; D003663:Decision Trees; D004334:Drug Administration Schedule; D005334:Fever / Q000139:chemically induced / Q000188:drug therapy* / Q000517:prevention & control; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D009503:Neutropenia / Q000139:chemically induced / Q000188:drug therapy* / Q000517:prevention & control; D018579:Patient Selection; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D018570:Risk Assessment; D014481:United States
D000970:Antineoplastic Agents; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; C455861:pegfilgrastim; D011092:Polyethylene Glycols; C081222:sargramostim; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D000069585:Filgrastim